SCHEDULE 13D/A: Shareholder Activist ADAR1 Capital Demands Keros Therapeutics Board Waive Nomination Deadline, Citing Fiduciary Breaches

ADAR1 Capital Management, the largest stockholder of Keros Therapeutics, Inc., has sent a letter to the Board of Directors demanding an immediate waiver or amendment of the annual meeting director nomination deadline, citing alleged breaches of fiduciary duties and actions taken to entrench current directors.

Summary

• ADAR1 Capital Management, the largest stockholder of Keros Therapeutics, Inc., sent a letter to the Board of Directors on April 24, 2025, alleging breaches of fiduciary duties.
• ADAR1 demands the Board immediately waive or amend the deadline for stockholders to nominate candidates for election to the Board at the Annual Meeting scheduled for June 4, 2025, noting the original deadline was February 28, 2025.
• The letter cites three key actions by the Board taken after the nomination deadline: initiating a formal review process for strategic alternatives (April 10, 2025), adopting a limited duration stockholder rights plan (Poison Pill) (April 10, 2025), and entering into a Standstill Agreement with Pontifax (April 18, 2025).
• The strategic review process, which could include a sale of the company, followed disappointing results from the Phase 1 clinical trial of KER-065 announced on March 31, 2025.
• The Standstill Agreement with Pontifax includes a provision for Pontifax to support the Company's director slate, which ADAR1 views as an attempt to manipulate corporate machinery.
• ADAR1 views these actions as 'radical shifts' and 'inequitable manipulation' designed to entrench current directors.
• The Reporting Persons (ADAR1 Capital Management, ADAR1 Capital Management GP, and Daniel Schneeberger) intend to discuss corporate governance, including Board composition, and may seek Board representation.
• They may communicate with other shareholders and/or third parties and may conduct a solicitation of proxies for the Annual Meeting.

Sentiment

Score: 3

Explanation: The document reflects a highly negative sentiment from a significant shareholder (ADAR1 Capital Management) towards Keros Therapeutics' Board of Directors, alleging breaches of fiduciary duties and manipulation of corporate governance. This indicates a contentious relationship and potential for significant shareholder activism and legal challenges.

Negatives

• Alleged breaches of fiduciary duties by Keros Therapeutics' Board of Directors.
• Board's refusal to waive or amend the director nomination deadline (February 28, 2025) despite significant post-deadline strategic shifts.
• Initiation of a formal strategic review process and adoption of a 'Poison Pill' after the director nomination deadline.
• Entry into a Standstill Agreement with Pontifax, including a 'Company Slate Support Provision,' which ADAR1 views as an attempt to entrench the incumbent Board.
• Disappointing results from the Phase 1 clinical trial of KER-065 announced on March 31, 2025, preceding the strategic review announcement.
• Alleged manipulation of corporate machinery by the Board to affect shareholders' right to conduct a contested election of directors.

Risks

• Potential litigation against Keros Therapeutics' directors by ADAR1 Capital Management for alleged breaches of fiduciary duties.
• Risk of a 'vote no' proxy campaign soliciting shareholders to withhold votes from directors Mary Ann Gray and Alpna Seth at the 2025 Annual Meeting.
• Increased shareholder activism and potential for a proxy contest, leading to corporate instability.
• Uncertainty regarding the outcome of the formal strategic review process, which could include a sale of the company or other business combination.
• The 'Poison Pill' could deter potential acquirers or significantly dilute existing shareholders if triggered, impacting shareholder value.
• Potential for distraction and diversion of management and Board resources due to the ongoing governance dispute.

Future Outlook

The Reporting Persons intend to have discussions with the Board and management regarding corporate governance, including the composition of the Board, and may seek representation on the Board. They may also communicate with other shareholders and/or third parties and conduct a solicitation of proxies in connection with any matters to be considered at the Annual Meeting. ADAR1 reserves all rights to pursue remedies, including a 'vote no' proxy campaign against directors Mary Ann Gray and Alpna Seth, and/or commencing litigation in the Delaware Court of Chancery if the Board refuses to waive or amend the nomination deadline.

Management Comments

• The Board has taken numerous actions that materially alter the status quo at the Company and appear calculated to entrench the current directors in office. (ADAR1's counsel's statement about the Board)
• The Board's decision to evaluate strategic alternatives came less than two weeks after the Company announced disappointing results from its Phase 1 clinical trial of KER-065. (ADAR1's counsel's statement about the Board)
• It appears to us that the Board may have threatened to drop Mr. Nussbaum from the Company's slate of nominees unless Pontifax agreed to support the Company's slate. That is a blatant manipulation of the corporate machinery for the sole purpose of entrenching the incumbent Board in office. (ADAR1's counsel's statement about the Board)

Industry Context

This filing highlights a common scenario in the biotech/pharmaceutical industry where clinical trial results can significantly impact company strategy and shareholder sentiment. Disappointing trial results often lead to strategic re-evaluations, which can then trigger shareholder activism if governance decisions are perceived as not aligning with shareholder interests. The use of a 'poison pill' and standstill agreements are defensive tactics often employed by boards facing activist investors, which are frequently challenged in the context of corporate governance best practices.

Comparison to Industry Standards

• The Board's actions, such as initiating a strategic review and adopting a poison pill after the director nomination deadline, are being challenged as potentially breaching fiduciary duties under Delaware law, which emphasizes the 'sacrosanct' nature of stockholder voting rights.
• The letter cites legal precedents like *Hubbard v. Hollywood Park Realty Enterprises, Inc.* and *Icahn Partners LP v. Amylin Pharmaceuticals, Inc.*, which suggest that radical shifts in company strategy or material changes in circumstances after a nomination deadline may obligate a board to waive advance notice requirements to ensure fair shareholder franchise.
• The Standstill Agreement with Pontifax, particularly the 'Company Slate Support Provision,' is criticized as an 'inequitable manipulation of the corporate machinery' that adversely affects shareholders' right to a contested election, referencing cases like *Schnell v. Chris-Craft Indus., Inc.* and *Healthcor Management, L.P. et al., v. Allscripts Healthcare Solutions, Inc.*.
• The adoption of a poison pill in conjunction with other actions after the nomination window is viewed as potentially constraining the voting power of those seeking a proxy contest, a practice often scrutinized by courts.

Corporate Governance

Legal Proceedings

• ADAR1 Capital Management reserves all rights to pursue any and all avenues available to remedy the directors' flagrant breaches of their fiduciary duties, including, but not limited to, commencing litigation against the Company's directors in the Delaware Court of Chancery.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if strategic alternatives are successfully pursued, but also risk of dilution from poison pill or prolonged governance dispute. Opportunity for greater influence if ADAR1's demands are met.
• Board of Directors: Under increased scrutiny and potential legal challenge, facing pressure to respond to ADAR1's demands.
• Management: May face distraction and pressure due to governance dispute.
• Employees: Uncertainty regarding future strategic direction (e.g., sale of company) could impact morale.

Next Steps

• Keros Therapeutics Board to confirm by April 28, 2025, at noon EDT, whether it will waive or amend the Nomination Deadline to allow a ten-day period for nominations.
• Keros Therapeutics Board to confirm it will not enforce the Company Slate Support Provision.
• Reporting Persons intend to have discussions with the Board and management regarding corporate governance and Board composition.
• Reporting Persons may seek representation on the Board.
• Reporting Persons may communicate with other shareholders and/or third parties.
• Reporting Persons may conduct a solicitation of proxies for the Annual Meeting.
• ADAR1 reserves rights to pursue remedies, including a 'vote no' proxy campaign against directors Mary Ann Gray and Alpna Seth.
• ADAR1 reserves rights to commence litigation against the Company's directors in the Delaware Court of Chancery.

Key Dates

Recommendation

Keywords

Keros Therapeutics, ADAR1 Capital Management, Schedule 13D, SEC filing, corporate governance, shareholder activism, proxy contest, director nomination, fiduciary duties, strategic alternatives, poison pill, standstill agreement, Pontifax, KER-065, clinical trial, biotech, pharmaceuticals